In non-small cell lung cancer (NSCLC), CAFs enhance the sensitivity to targeted drugs like EGFR-TKI by secreting insulin-like growth factor (IGF) and IGF-binding proteins (IGFBPs). This evidence concerns the gene EGFR and non-small cell lung carcinoma.